Neuronetics (NASDAQ:STIM – Get Rating) and Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Insider and Institutional Ownership
62.9% of Neuronetics shares are held by institutional investors. Comparatively, 66.7% of Alpha Healthcare Acquisition Corp. III shares are held by institutional investors. 5.2% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Neuronetics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Alpha Healthcare Acquisition Corp. III has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neuronetics||$65.21 million||1.20||-$37.16 million||($1.38)||-1.99|
|Alpha Healthcare Acquisition Corp. III||N/A||N/A||$200,000.00||N/A||N/A|
Alpha Healthcare Acquisition Corp. III has lower revenue, but higher earnings than Neuronetics.
This is a breakdown of current ratings and target prices for Neuronetics and Alpha Healthcare Acquisition Corp. III, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alpha Healthcare Acquisition Corp. III||0||0||0||0||N/A|
Neuronetics currently has a consensus price target of $9.67, suggesting a potential upside of 252.16%. Given Neuronetics’ higher possible upside, equities analysts plainly believe Neuronetics is more favorable than Alpha Healthcare Acquisition Corp. III.
This table compares Neuronetics and Alpha Healthcare Acquisition Corp. III’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alpha Healthcare Acquisition Corp. III||N/A||-3.67%||0.13%|
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
About Alpha Healthcare Acquisition Corp. III
Alpha Healthcare Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses or entities. It focuses to source, acquire, and manage a business in the healthcare industry in the United States. The company was incorporated in 2021 and is based in New York, New York.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.